Medicare recently announced that it selected 15 high-cost prescription drugs, including Botox and Trulicity, for government price negotiations under the Inflation Reduction Act.
The Centers for Medicare & Medicaid Services (CMS) said the third round of negotiations will target medications that account for roughly $27 billion in annual Medicare spending.
Trulicity, a widely used treatment for type 2 diabetes, and Botox, used medically for conditions such as chronic migraines and overactive bladder, are on the list.
CMS said these talks aim to lower costs for older adults and people with disabilities, and results are expected to take effect in 2028.
The negotiation round also includes other drugs for HIV, cancer, and autoimmune diseases, marking the first time some Medicare Part B drugs are eligible.